PT  - JOURNAL ARTICLE
AU  - Rachel M. Bartlett
AU  - Robert J. Nickles
AU  - Todd E. Barnhart
AU  - Bradley T. Christian
AU  - James E. Holden
AU  - Onofre T. DeJesus
TI  - Fetal Dose Estimates for <sup>18</sup>F-Fluoro-<span class="sc">l</span>-Thymidine Using a Pregnant Monkey Model
AID  - 10.2967/jnumed.109.068734
DP  - 2010 Feb 01
TA  - Journal of Nuclear Medicine
PG  - 288--292
VI  - 51
IP  - 2
4099  - http://jnm.snmjournals.org/content/51/2/288.short
4100  - http://jnm.snmjournals.org/content/51/2/288.full
SO  - J Nucl Med2010 Feb 01; 51
AB  - Estimating the radiation dose received by the fetus from nuclear medicine procedures is important because of the greater sensitivity of rapidly developing fetal tissues to ionizing radiation. 18F-fluoro-l-thymidine (FLT) uptake is related to cellular proliferation and is currently used to monitor tumor progression and response to therapy. This study was undertaken to estimate—on the basis of biodistribution data obtained by PET/CT in pregnant rhesus monkeys—radiation absorbed dose to a human fetus administered 18F-FLT. Methods: Three pregnant rhesus macaques (gestational age, 113 ± 8 d) were administered 18F-FLT and imaged for 2 h on a PET/CT scanner. Time–activity curves for maternal and fetal organs were generated in anatomic regions of interest identified via CT. Doses were estimated using OLINDA/EXM and the 6-mo-pregnant human model. Results: The extrapolated whole-body maternal dose obtained, 11.4 μGy/MBq, is similar to the previously reported adult female dose of 15.6 μGy/MBq. The estimated total-body dose to a human fetus is 24 μGy/MBq. Significant long-term 18F-FLT accumulation in fetal liver resulted in a fetal liver dose of 53 μGy/MBq. Conclusion: The fetal dose estimate in a 6-mo-pregnant human using 18F-FLT is slightly greater than that reported for 18F-FDG. 18F-FLT trapping in the fetal liver should be considered in the risk–benefit analysis of 18F-FLT PET examination in pregnant patients.